Praxis Precision announces topline results from Phase 2 RADIANT study

Praxis Precision (PRAX) Medicines announced topline results from the Phase 2 RADIANT study evaluating vormatrigine in patients with focal onset seizures. Summary: Dosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency; Approximately 22% of patients reached 100% reduction in seizure frequency in the last 28 days on treatment; Rapid and sustained response, with over 54% of patients achieving 50% response in the first week; Vormatrigine was generally well tolerated and continues to demonstrate favorable safety profile